🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are increasing globally, with data suggesting in excess of 82 million infections annually. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted available drugs presently on offer.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, alternatively called a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Global Access

According to data released by a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an equal footing with the current standard treatment, which combines an injection and a pill. The study enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the rights to register and commercialise the drug in many developing nations.

Doctors directly involved have shared positive views. Having a easy-to-administer therapy such as this is seen as a "critical tool" for public health efforts. This is deemed vital to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.